Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions.

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Significant progress in kidney cancer treatment.
• Checkpoint immunotherapies and novel targeted agents have emerged.

Purpose of the Study:

• Review current treatment strategies for metastatic renal cell carcinoma.
• Discuss future directions in kidney cancer therapy.

Main Methods:

• Literature review of recent advancements.
• Analysis of current treatment options and ongoing trials.

Main Results:

• New drugs (nivolumab, cabozantinib, lenvatinib/everolimus) show improved survival.
• Guidelines for treatment sequencing and biomarker selection are lacking.
• Ongoing trials explore combinations, timing, and personalized treatment.

Conclusions:

• Despite progress, unanswered questions remain in kidney cancer treatment.
• Personalized treatment based on tumor profiling shows promise.
• Further research is needed to establish evidence-based guidelines.